kebuzone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory analgesics, phenylbutazone derivatives 1522 853-34-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • kebuzone
  • chebutan
  • chetazol
  • chetazolidin
  • ketanol
  • ketazon
  • ketazone
  • ketophenylbutazone
proposed antirheumatic agent; minor descriptor (75-86); on-line & INDEX MEDICUS search PHENYLBUTAZONE/AA
  • Molecular weight: 322.36
  • Formula: C19H18N2O3
  • CLOGP: 0.90
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 57.69
  • ALOGS: -3.45
  • ROTB: 5

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.381 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.559 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 47.315 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 4.130 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 9.780 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 7.890 % Moderate 0.65
herg hERG pIC50 4.408 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 1.294 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 3.192 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 5.420 % Moderate 0.65
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK7,MAPK9,MARK4,MET,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK 43
kinase-selectivity-class AXL,GRK2 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 5.572 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 9.419 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 15.430 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.655 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 8.750 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 2.275 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 89.160 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 4.060 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 968.278 uM Moderate 0.65

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AA06 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Butylpyrazolidines
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35481 non-narcotic analgesic

Related Drugs by ATC class:

M01AA Butylpyrazolidines 4 drugs
clofezonemofebutazoneoxyphenbutazonephenylbutazone

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.38 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01567 KEGG_DRUG
C0064324 UMLSCUI
CHEBI:31749 CHEBI
CHEMBL2107720 ChEMBL_ID
DB08940 DRUGBANK_ID
C100280 MESH_SUPPLEMENTAL_RECORD_UI
3824 PUBCHEM_CID
2444 INN_ID
4VD83UL6Y6 UNII
28198 RXNORM
004197 NDDF

Pharmaceutical products:

None